Compare Freeport-McMoRan Inc (FCX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Organon & Co. Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.53 (market cap $104.00B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Freeport-McMoRan Inc is far larger — about 28.7× Organon & Co. Common Stock's market cap, and Freeport-McMoRan Inc pays the higher dividend (0.83%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Organon & Co. Common Stock for 0 Days on average.
| FCX | OGN | |
|---|---|---|
Market Cap | $104.00B | $3.62B |
Volume | 7,316,762 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $13.81 |
52-Week Low | $38.65 | $5.70 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $11.04B |
Dividend Yield | 0.83% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, down 5.01% today, but maintains strong technical momentum with bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Copper demand fundamentals remain robust, driven by AI infrastructure needs, while FCX's expansion projects position it for growth. Analyst consensus remains strongly bullish with a $73.27 price target.
FCX presents a compelling investment case with strong copper demand tailwinds and consistent earnings outperformance. However, rising production costs and a high P/E ratio of 35.5 warrant caution. The stock offers exposure to copper's structural deficit while carrying execution risks from expansion projects and commodity price volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
